AIMS: DSM-IV drug use disorders, a major public health problem, are highly comorbid with other psychiatric disorders, but little is known about the role of this comorbidity when studied prospectively in the general population. Our aims were to determine the role of comorbid psychopathology in the 3-year persistence of drug use disorders. DESIGN AND SETTING: Secondary data analysis using waves 1 (2001-02) and 2 (2005-05) of the National Epidemiologic Survey on Alcohol and Related Conditions. PARTICIPANTS: Respondents with current DSM-IV drug use disorder at wave 1 who participated in wave 2 (n = 613). MEASUREMENTS: Alcohol Use Disorders and Associated Disabilities Interview Schedule IV (AUDADIS-IV) obtained DSM-IV Axis I and II diagnoses. Persistent drug use disorder was defined as meeting full criteria for any drug use disorder between waves 1 and 2. FINDINGS: Drug use disorders persisted in 30.9% of respondents. No Axis I disorders predicted persistence. Antisocial [odds ratio (OR) = 2.75; 95% confidence interval (CI): 1.27-5.99], borderline (OR = 1.91; 95% CI: 1.06-3.45) and schizotypal (OR = 2.77; 95% CI: 1.42-5.39) personality disorders were significant predictors of persistent drug use disorders, controlling for demographics, psychiatric comorbidity, family history, treatment and number of drug use disorders. Deceitfulness and lack of remorse were the strongest antisocial criteria predictors of drug use disorder persistence, identity disturbance and self-damaging impulsivity were the strongest borderline criteria predictors, and ideas of reference and social anxiety were the strongest schizotypal criteria predictors. CONCLUSIONS: Antisocial, borderline and schizotypal personality disorders are specific predictors of drug use disorder persistence over a 3-year period. Published 2011. This article is a U.S. Government work and is in the public domain in the USA.
AIMS: DSM-IV drug use disorders, a major public health problem, are highly comorbid with other psychiatric disorders, but little is known about the role of this comorbidity when studied prospectively in the general population. Our aims were to determine the role of comorbid psychopathology in the 3-year persistence of drug use disorders. DESIGN AND SETTING: Secondary data analysis using waves 1 (2001-02) and 2 (2005-05) of the National Epidemiologic Survey on Alcohol and Related Conditions. PARTICIPANTS: Respondents with current DSM-IV drug use disorder at wave 1 who participated in wave 2 (n = 613). MEASUREMENTS: Alcohol Use Disorders and Associated Disabilities Interview Schedule IV (AUDADIS-IV) obtained DSM-IV Axis I and II diagnoses. Persistent drug use disorder was defined as meeting full criteria for any drug use disorder between waves 1 and 2. FINDINGS: Drug use disorders persisted in 30.9% of respondents. No Axis I disorders predicted persistence. Antisocial [odds ratio (OR) = 2.75; 95% confidence interval (CI): 1.27-5.99], borderline (OR = 1.91; 95% CI: 1.06-3.45) and schizotypal (OR = 2.77; 95% CI: 1.42-5.39) personality disorders were significant predictors of persistent drug use disorders, controlling for demographics, psychiatric comorbidity, family history, treatment and number of drug use disorders. Deceitfulness and lack of remorse were the strongest antisocial criteria predictors of drug use disorder persistence, identity disturbance and self-damaging impulsivity were the strongest borderline criteria predictors, and ideas of reference and social anxiety were the strongest schizotypal criteria predictors. CONCLUSIONS: Antisocial, borderline and schizotypal personality disorders are specific predictors of drug use disorder persistence over a 3-year period. Published 2011. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Wilson M Compton; Linda B Cottler; Jacqueline L Jacobs; Arbi Ben-Abdallah; Edward L Spitznagel Journal: Am J Psychiatry Date: 2003-05 Impact factor: 18.112
Authors: Bridget F Grant; Deborah A Dawson; Frederick S Stinson; Patricia S Chou; Ward Kay; Roger Pickering Journal: Drug Alcohol Depend Date: 2003-07-20 Impact factor: 4.492
Authors: Frederick S Stinson; Deborah A Dawson; Risë B Goldstein; S Patricia Chou; Boji Huang; Sharon M Smith; W June Ruan; Attila J Pulay; Tulshi D Saha; Roger P Pickering; Bridget F Grant Journal: J Clin Psychiatry Date: 2008-07 Impact factor: 4.384
Authors: Deborah Hasin; Miriam C Fenton; Andrew Skodol; Robert Krueger; Katherine Keyes; Timothy Geier; Eliana Greenstein; Carlos Blanco; Bridget Grant Journal: Arch Gen Psychiatry Date: 2011-11
Authors: Katherine M Keyes; Magdalena Cerdá; Joanne E Brady; Jennifer R Havens; Sandro Galea Journal: Am J Public Health Date: 2013-12-12 Impact factor: 9.308
Authors: Jennifer C Elliott; Malka Stohl; Melanie M Wall; Katherine M Keyes; Renee D Goodwin; Andrew E Skodol; Robert F Krueger; Bridget F Grant; Deborah S Hasin Journal: Addiction Date: 2014-02-16 Impact factor: 6.526
Authors: Alvaro Vergés; Matt G Kushner; Kristina M Jackson; Kathleen K Bucholz; Timothy J Trull; Sean P Lane; Kenneth J Sher Journal: J Anxiety Disord Date: 2013-10-14